Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 10/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 4/20 | 0.47 |
| ▸ | MAOB | P27338 | 4/20 | 0.47 |
| ▸ | PRF1 | P14222 | 3/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2724252 | 0.85 | KCNJ1 (0.59) | KCNJ1KCNH2MAPTLMNAGAA | |
| SCHEMBL2722639 | 0.81 | KCNJ1 (0.66) | KCNJ1KCNH2MAPTLMNAGAA | |
| SCHEMBL19367891 | 0.81 | KCNJ1 (0.66) | KCNJ1KCNH2MAPTLMNAGAA | |
| SCHEMBL286654 | 0.81 | KCNJ1 (0.66) | KCNJ1KCNH2MAPTLMNAGAA | |
| SCHEMBL6104061 | 0.78 | KCNJ1 (0.62) | KCNJ1KCNH2MAPTLMNAGAA | |
| SCHEMBL18199329 | 0.78 | KCNJ1 (0.62) | KCNJ1KCNH2MAPTLMNAGAA | |
| SCHEMBL16107505 | 0.77 | KCNJ1 (0.51) | KCNJ1KCNH2MAPTLMNAGAA | |
| SCHEMBL4305292 | 0.77 | KCNJ1 (0.61) | KCNJ1KCNH2MAPTLMNAGAA | |
| SCHEMBL10233877 | 0.77 | KCNJ1 (1.00) | KCNJ1KCNH2 | |
| SCHEMBL13870507 | 0.77 | KCNJ1 (0.60) | KCNJ1KCNH2MAPTLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004084-A1 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004084-A1 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | CDK2, ERBB2, MAP3K3 | KCNJ1 3104/4885KCNH2 1780/4885MAPT 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.